Aurobindo Pharma vs Glenmark Pharmaceuticals: Share Price, Valuation and Results Compared

Aurobindo Pharma Ltd. (NSE: AUROPHARMA) and Glenmark Pharmaceuticals Limited (NSE: GLENMARK) are both listed in the Medicinal Chemicals and Botanical Products industry. Aurobindo Pharma has a market capitalisation of ₹1,05,150 Cr and Glenmark Pharmaceuticals ₹75,556 Cr, as of 16 Nov 2026. Their P/E ratios are 30 and 55.1 respectively. Return on equity is 9.93% for Aurobindo Pharma and 14.07% for Glenmark Pharmaceuticals. Over one year, Aurobindo Pharma's share price is up 59.8% and Glenmark Pharmaceuticals's is up 45.7%.

Aurobindo Pharma vs Glenmark Pharmaceuticals — Key Figures

MetricAurobindo PharmaGlenmark Pharmaceuticals
NSE SymbolAUROPHARMAGLENMARK
BSE Code524804532296
Share Price₹1,823.20₹2,640.00
Market Cap₹1,05,150 Cr₹75,556 Cr
P/E Ratio3055.1
Return on Equity9.93%14.07%
Return on Assets5.95%14.11%
Dividend Yield0.00%0.19%
Beta (1Y)0.060.23
1-Year Price Change+59.8%+45.7%
3-Month Price Change+9.6%+13.8%
52-Week Range₹1,106.00 – ₹1,859.90₹1,810.00 – ₹2,714.00
Latest QuarterQ2 FY27Q2 FY27
Quarterly Revenue₹10,263 Cr₹4,157 Cr
Quarterly Net Profit₹1,124 Cr₹264 Cr
Net Margin11.0%6.3%
EPS (Basic, Quarter)₹19.57₹9.35
Results Basisconsolidatedconsolidated
HeadquartersHyderabad, TelanganaMumbai, Maharashtra

The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.

About the Companies

Aurobindo Pharma Ltd.

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HI…

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topica…

Frequently Asked Questions

Which is larger by market cap, Aurobindo Pharma or Glenmark Pharmaceuticals?

Aurobindo Pharma has a market capitalisation of ₹1,05,150 Cr, against ₹75,556 Cr for Glenmark Pharmaceuticals as of 16 Nov 2026, about 1.4 times the size by market cap.

What is the P/E ratio of Aurobindo Pharma and Glenmark Pharmaceuticals?

Aurobindo Pharma has a P/E of 30 and Glenmark Pharmaceuticals a P/E of 55.1 as of 16 Nov 2026.

What is the return on equity of Aurobindo Pharma and Glenmark Pharmaceuticals?

Aurobindo Pharma has a return on equity of 9.93% and Glenmark Pharmaceuticals 14.07%.

How have Aurobindo Pharma and Glenmark Pharmaceuticals shares moved over one year?

Aurobindo Pharma's share price is up 59.8% over one year and Glenmark Pharmaceuticals's is up 45.7%.

What were the latest quarterly results of Aurobindo Pharma and Glenmark Pharmaceuticals?

Aurobindo Pharma reported revenue of ₹10,263 Cr and net profit of ₹1,124 Cr for Q2 FY27. Glenmark Pharmaceuticals reported revenue of ₹4,157 Cr and net profit of ₹264 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.

Which industry are Aurobindo Pharma and Glenmark Pharmaceuticals in?

Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.

Is this comparison a recommendation to buy or sell Aurobindo Pharma or Glenmark Pharmaceuticals?

No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.

More Comparisons

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.